

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 28th January, 2019

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id : 506365

Subject : **SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Quarter ended 31st December, 2018 as under -


1.	Regulation 33	Un-audited Quarterly Financial Results along with Statement of Assets And Liabilities for the Quarter ended 31/12/2018 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 28/01/2019

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)





VMD & CO.
CHARTERED ACCOUNTANTS

AVMS PREMISES,
4TH FLOOR,
SHREENIWAS HOUSE,
27, H.S. MARG, FORT,
MUMBAI- 400 001
Telefax : +91 22 2207 7707
Email : info@vmd.co.in
www.vmd.co.in

LIMITED REVIEW REPORT

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **31st December, 2018**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For M/s VMD & CO.
Chartered Accountants.
FRN: 125002W


CA AMIT GANPULE
PARTNER
MRN: 114222

NO: C/01/0119
Dated: 28/01/2019
Place: MUMBAI

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com


UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON 31ST DECEMBER, 2018

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31st Dec. 2018	30th Sept., 2018	31st Dec. 2017	31st Dec. 2018	31st Dec. 2017	31st March 2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations		-	-		-	-
II	Other Income	1,420	1,299	3,225	3,959	6,943	11,055
III	Total Revenue (I + II)	1,420	1,299	3,225	3,959	6,943	11,055
IV	Expenses						
	Cost Materials consumed	-	-	-	-	-	-
	Purchase of Stock-in-Trade	-	-	-	-	-	-
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	Employee Benefits Expenses	624	506	403	1,692	1,167	1,564
	Depreciation and Amortisation Expenses	-	-	-	-	-	35
	Other Expenses (Any Item exceeding 10% of the Total Expenses relating to continuing Operations to be shown separately)	284	533	26	1,497	350	417
	i) Professional Charges	125	188	660	420	735	991
	ii) Share Registry Expenses	269	-	41	347	77	100
	iii) Annual Listing Fees	-	-	-	310	315	315
	iv) Postal Charges	-	201	-	57	-	-
	Finance Costs	-	-	-	-	-	-
	Total Expenses	1,302	1,428	1,130	4,323	2,644	3,422
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	118	(129)	2,095	(364)	4,299	7,633
VI	Exceptional Items	-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	118	(129)	2,095	(364)	4,299	7,633
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	118	(129)	2,095	(364)	4,299	7,633
X	Tax Expenses						
	(1) Current Tax	-	-	-	-	5,177	1,450
	(2) Tax Adjusted Previous Year	-	-	-	-	-	5,177
	(3) Deferred Tax	-	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	118	(129)	2,095	(364)	(878)	1,006
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	118	(129)	2,095	(364)	(878)	1,006
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period	118	(129)	2,095	(364)	(878)	1,006
XVIII	Earnings per Share :						
	(1) Basic	0.08	(0.09)	1.40	(0.24)	(0.59)	0.67
	(2) Diluted						

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Un-Audited Financial Results for the Quarter and Nine Months Ended 31.12.2018 have been reviewed by the Audit Committee in their Meeting held on 28.01.2019 and approved by the Board of Directors of its Meeting held on 28.01.2019. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
 DIRECTOR
 (DIN NO. - 03063364)



Place : Mumbai

Date : 28th January, 2019

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDLONE NET PROFIT FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2018

(Rs. In Thousand)

PARTICULARS	STANDLONE	
	UNAUDITED QUARTER ENDED 31.12.2018	UNAUDITED NINE MONTHS ENDED 31.12.2018
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	118.00	(364.00)
Benefit / (Charge):	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
Net Profit / (Loss) for the Period (as per AS)	118.00	(364.00)

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)



Mumbai, 28th January, 2019